WHAT WE DO
PHD Biosciences (PHD) is a clinical-stage biopharmaceutical company developing technologies for diseases with high unmet medical need. Our expert team is developing in-house and in-licensed technologies, and works closely with our academic and industrial partners to rapidly develop promising technologies through early stage clinical trials. PHD programs have won 16 awards since 2011 totaling more than $9.5 million in nondilutive financing to accelerate the development of our translational technologies.
When in-licensing technologies, the involvement of the academic principal investigator (PI) is important to us and we engage in a collaborative model that leverages the PI’s expertise through university subcontracts and other mechanisms. This helps secure the PI’s invovlment through the development and commercialization process.
An initial investment in new programs is financed 100% in-house, and promising technologies are advanced using combinations of non-dilutive and dilutive funding. Strategic investment partners are recruited as needed, and utilized to accelerate the development of promising programs through clinical trials.
PHD DERMATOLOGY ASSETS
The PHD dermatology pipeline comprises several products that are being developed through 505(b)(2) New Drug Applications for a variety of indications. Please see the INNOVATIONS page for information.
OTC AND SKIN CARE PRODUCTS
The over the counter (OTC) drug and skin care commercial product portfolio is managed by an independent team at PHD Skin Care. Please visit www.phdskincare.com, or email firstname.lastname@example.org for information.
INFO@PHDBIOSCIENCES | 646.801.3872 | 180 VARICK STREET, SUITE 526, NEW YORK, NY 10014 ©2017 PHDBIOSCIENCES